Medical Device | January 10, 2024
Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Subscribe To Our Newsletter & Stay Updated
